In his weekly clinical update, Dr. Griffin discusses Florida local transmission of dengue cases reported in Broward and Miami-Dade counties, infants admitted to US intensive care units for RSV infection during the 2022 seasonal peak, long-term risk of death and readmission after hospital admission with COVID-19 among older adults, safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic kidney disease and COVID-19, Fluvoxamine vs placebo for outpatients with symptomatic COVID-19, the effect of corticosteroids, antibiotics, and anticoagulants on the development of post-COVID-19 syndrome in COVID-19 hospitalized patients 6 months after discharge, long COVID and significant activity limitation among adults, incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong, and diabetes following SARS-CoV-2 infection: Incidence, persistence, and implications of COVID-19 vaccination.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Florida local transmission of dengue cases (Outbreak News)
• Infants admitted to US ICU for RSV infection (JAMA)
• Long term risk of death and readmission after hospital admission with COVID-19 (BMJ)
• Outcomes of Nirmatrelvir-Ritonavir Treatment in patients with Kidney disease and COVID-19 (CID)
• Fluvoxamine vs placebo for outpatients with symptomatic COVID-19 (OFID)
• The effect of corticosteroids, antibiotics, and anticoagulants on the development of post-COVID-19 syndrome in hospitalized patients (CEM)
• Long COVID and significant activity limitation among adults (CDC)
• Incidence of Diabetes following COVID-19 vaccination and SARS-CoV-2 infection (PLOS)
• Diabetes following SARS-CoV-2 infection (BMJ)
• Contribute to our Floating Doctors fundraiser at PWB
• Letters read on TWiV 1036
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]